-
Inventory of biological products approved for marketing in 2015
Time of Update: 2016-02-24
Recently, CFDA released the approval of drug listing in 2015 According to statistics, in 2015, the State Food and Drug Administration approved 76 applications for listing registration of traditional C
-
Two class 1.1 heavyweight new drugs of synthetic pharmaceutical industry settled in China Pharmaceutical City
Time of Update: 2016-02-23
On February 23, 2016, major innovation projects of Synthetic Medicine (832077) were successfully signed and settled in China Pharmaceutical city According to reports, Shaanxi Synthetic Pharmaceutical
-
The future domestic market of hepatitis C DAA: who is in charge of ups and downs?
Time of Update: 2016-02-23
This time, the domestic manufacturers are very ambitious, in order to let the Chinese enjoy the oral hepatitis C therapy, but also show their magic power And for companies that do not have a ready DAA joint program in hand, the most important is: joint!
-
Hengrui's 2 billion + blockbuster new drug hhpg-19k is about to go on the market!
Time of Update: 2016-02-22
On February 20, the registration status of Hengrui pharmaceutical's polyethylene glycol recombinant human granulocyte stimulating factor injection (hhpg-19k) changed to "under triad review", and it is
-
Zhongsheng Pharmaceutical Co develops a new drug zsym006 for the treatment of liver cancer
Time of Update: 2016-02-22
Announcement of Guangdong Zhongsheng Pharmaceutical Co., Ltd on the signing of Technology Development (cooperation) contract between the company and Shanghai yaomingkant new drug development Co., Ltd
-
CDE drug review weekly report (February 15, 2016 to February 20, 2016)
Time of Update: 2016-02-22
This week's focus declaration 1 This week, only 50 drugs (according to the acceptance number, the same below) entered the review status, and the declaration volume has been kept at a relatively low le
-
Wuxi apptec will go to Hong Kong again and focus on new drug research and development in the future
Time of Update: 2016-02-18
Recently, it was reported that Chinese pharmaceutical company Wuxi Kant is considering listing in Hong Kong and plans to raise about 300 million US dollars, equivalent to about 2.34 billion Hong Kong
-
Jiangsu Wanbang, a subsidiary of Fosun Pharmaceutical, withdraws the application for production of new diabetes drugs
Time of Update: 2016-02-11
Fosun Pharmaceutical (600196) (02196) announced that recently, according to the latest drug review policy of the State Food and drug administration, and combined with the actual situation, Jiangsu Wan
-
CDE drug review weekly report (February 1, 2016 to February 7, 2016)
Time of Update: 2016-02-08
Point 1: this week, there are 134 drugs (calculated according to the acceptance number, the same below), of which 133 chemicals, most of which have been withdrawn by announcement, including a 1.1 new
-
Ac0058, a new class 1.1 drug of Eisen medicine, has been approved by FDA
Time of Update: 2016-02-06
Hangzhou Essen Pharmaceutical Research Co., Ltd (hereinafter referred to as "Essen pharmaceutical") independently developed the national class 1.1 innovative drug ac0058, which was recently approved b
-
First class new drug of Tianjin Pharmaceutical Research Institute
Time of Update: 2016-02-05
Zhifei zaxaban (ty602), a new drug independently developed and designed by Tianjin Pharmaceutical Research Institute, has been approved for clinical application It is the first anti coagulation drug i
-
CDE drug review weekly report (January 26, 2016 to January 31, 2016)
Time of Update: 2016-02-01
Highlight 1 - class 1.1 chemicals under review this week: 1) amxetine hydrochloride enteric coated tablets: This product is declared by the Institute of toxicants and drugs, Academy of Military Medica
-
Zhongsheng Pharmaceutical Co., Ltd. and Wuxi apptec develop new drugs zsym005 for the treatment of influenza A and human avian influenza
Time of Update: 2016-02-01
Announcement of Guangdong Zhongsheng Pharmaceutical Co., Ltd on the signing of Technology Development (cooperation) contract between the company and Shanghai yaomingkant new drug development Co., Ltd
-
The concept of "patients participating in drug research and development" is valued
Time of Update: 2016-02-01
Pharmaceutical executives believe that greater patient and public participation can improve drug research and development, according to a new study The study, published in BMJ open, is the first in th
-
China drug approval inventory in 2015
Time of Update: 2016-01-30
In 2015, when the policy changed dramatically, the declaration of generic drugs and imported drugs shrank, and CDE also made full efforts to review them How many drugs did CFDA approve this year? Whic
-
CDE drug review weekly report (January 18, 2016 to January 25, 2016)
Time of Update: 2016-01-26
There are a lot of key drugs and key drugs Please read them patiently Maybe you focus on the last part: 1 Nanofloxacin malate capsule: This product was mentioned last week, and the three in one review
-
Cetifloxacin tablets, a class 3.1 new drug of Laimei pharmaceutical industry, obtained the approval of clinical trials
Time of Update: 2016-01-25
Laimei pharmaceutical announced in the evening of January 22 that the company had recently received the approval document and notice of approval opinions for clinical trials of drugs issued by the Sta
-
High price counter attack! Six new drugs transfer amount explosion table of domestic pharmaceutical enterprises
Time of Update: 2016-01-21
Recently, the news that Zhengda Tianqing has transferred new hepatitis drugs to Johnson & Johnson with us $250 million has aroused heated discussion In fact, with the improvement of R & D capacity, do
-
Collapse · drug companies withdraw varieties like a flood (Part 4)
Time of Update: 2016-01-21
It's almost a month since 2015 It seems that pharmaceutical companies haven't made 2016 plans, right? That said, how to do it?! This has been listed varieties, bidding is to haggle over the price, at
-
CDE drug review weekly report (January 11, 2016 to January 17, 2016)
Time of Update: 2016-01-18
Here's the point There are too many points this week Let's open our eyes and take a closer look In review 1, cabotinib malic acid capsule: developed by exelixis Inc, it can inhibit the following recep
